National Institute on Drug Abuse; Notice of Closed Meetings, 75179 [2012-30453]
Download as PDF
<![CDATA[
Federal Register / Vol. 77, No. 244 / Wednesday, December 19, 2012 / Notices
sroberts on DSK5SPTVN1PROD with
hearing and are encouraged to arrive
early to ensure the designated order of
presentation times. We will try to
accommodate all persons who wish to
present; however, the duration of each
speaker’s testimony may be limited by
time constraints. An agenda of the
meeting and other background material
will be made available 5 days before the
meeting at https://www.fda.gov/Drugs/
NewsEvents/ucm326450.htm.
Questions about the meeting may also
be also submitted to
IssuesWithOpioids@fda.hhs.gov prior to
the February 7 and February 8, 2013,
meeting dates.
The hearing is free and seating will be
on a first-come, first-served basis. Early
registration is recommended because
seating is limited. FDA may limit the
numbers of participants from individual
organizations as well as total number of
attendees based on space limitations.
Registrants will receive confirmation
once they have been accepted to attend
the hearing. For those who cannot
attend in person, information regarding
viewing a live Web cast of the public
hearing will be located at: https://
www.fda.gov/Drugs/NewsEvents/
ucm326450.htm.
If you need special accommodations
due to a disability, contact Elizabeth
Giaquinto or Mary Gross (see FOR
FURTHER INFORMATION CONTACT).
IV. Notice of Hearing Under 21 CFR
Part 15
The Commissioner of Food and Drugs
is announcing that the public hearing
will be held in accordance with part 15
(21 CFR part 15). The hearing will be
conducted by a presiding officer, who
will be accompanied by FDA senior
management from the Center for Drug
Evaluation and Research.
Under § 15.30(f), the hearing is
informal and the rules of evidence do
not apply. No participant may interrupt
the presentation of another participant.
Only the presiding officer and panel
members may question any person
during or at the conclusion of each
presentation. Public hearings under part
15 are subject to FDA’s policy and
procedures for electronic media
coverage of FDA’s public administrative
proceedings (part 10 (21 CFR part 10),
subpart C). Under § 10.205,
representatives of the electronic media
may be permitted, subject to certain
limitations, to videotape, film, or
otherwise record FDA’s public
administrative proceedings, including
presentations by participants.
The hearing will be transcribed as
stipulated in § 15.30(b). A transcript
will be available for review at the
Division of Dockets Management (see
VerDate Mar<15>2010
16:35 Dec 18, 2012
Jkt 229001
ADDRESSES) and on the Internet at
https://www.regulations.gov within 30
days of the meeting. A transcript will
also be available in either hard copy or
on CD–ROM after submission of a
Freedom of Information request. Submit
written requests to the Division of
Freedom of Information (ELEM–1029),
Office of Management Programs, Food
and Drug Administration, 12420
Parklawn Dr., Element Bldg., Rockville,
MD 20857.
To the extent that the conditions for
the hearing, as described in this notice,
conflict with any provisions set out in
part 15, this notice acts as a waiver of
those provisions as specified in
§ 15.30(h).
V. Request for Comments
Interested persons may submit to the
Division of Dockets Management (see
ADDRESSES) either electronic or written
comments for consideration by April 8,
2013. Persons who wish to provide
additional materials for consideration
should file these materials with the
Division of Dockets Management. You
should annotate and organize your
comments so that they identify the
specific questions to which they refer. It
is only necessary to send one set of
comments. Identify comments with the
docket number found in brackets in the
heading of this document. Received
comments may be seen in Division of
Dockets Management between 9 a.m.
and 4 p.m., Monday through Friday, and
will be posted to the docket at https://
www.regulations.gov.
Dated: December 13, 2012.
Leslie Kux,
Assistant Commissioner for Policy.
[FR Doc. 2012–30516 Filed 12–18–12; 8:45 am]
BILLING CODE 4160–01–P
75179
proposals, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel;
N43DA13–4417: Video Gaming Targeting
Relapse Prevention in Youth with Substance
Use Disorders.
Date: January 9, 2013.
Time: 9:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852, (Telephone
Conference Call).
Contact Person: Nadine Rogers, Ph.D.,
Scientific Review Officer, Office of
Extramural Affairs, National Institute on
Drug Abuse, NIH, DHHS, 6001 Executive
Blvd., Room 4229, MSC 9550, Bethesda, MD
20892–9550, 301–402–2105,
rogersn2@nida.nih.gov.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel; Profile
Screening and Predictive Toxicology (8909).
Date: February 12, 2013.
Time: 10:00 a.m. to 2:00 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852, (Telephone
Conference Call).
Contact Person: Lyle Furr, Contract Review
Specialist, Office of Extramural Affairs,
National Institute on Drug Abuse, NIH,
DHHS, Room 4227, MSC 9550, 6001
Executive Boulevard, Bethesda, MD 20892–
9550, (301) 435–1439, lf33c.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos.: 93.279, Drug Abuse and
Addiction Research Programs, National
Institutes of Health, HHS)
Dated: December 13, 2012.
Michelle Trout,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2012–30453 Filed 12–18–12; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institute on Drug Abuse;
Notice of Closed Meetings
National Institutes of Health
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 USC,
as amended. The contract proposals and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable materials,
and personal information concerning
individuals associated with the contract
National Institute on Drug Abuse
Notice of Closed Meetings
PO 00000
Frm 00075
Fmt 4703
Sfmt 4703
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable materials,
E:\FR\FM\19DEN1.SGM
19DEN1
]]>Agencies
[Federal Register Volume 77, Number 244 (Wednesday, December 19, 2012)]
[Notices]
[Page 75179]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2012-30453]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse; Notice of Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App), notice is hereby given of the following
meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
USC, as amended. The contract proposals and the discussions could
disclose confidential trade secrets or commercial property such as
patentable materials, and personal information concerning individuals
associated with the contract proposals, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; N43DA13-4417: Video Gaming Targeting Relapse
Prevention in Youth with Substance Use Disorders.
Date: January 9, 2013.
Time: 9:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate contract proposals.
Place: National Institutes of Health, Neuroscience Center, 6001
Executive Boulevard, Rockville, MD 20852, (Telephone Conference
Call).
Contact Person: Nadine Rogers, Ph.D., Scientific Review Officer,
Office of Extramural Affairs, National Institute on Drug Abuse, NIH,
DHHS, 6001 Executive Blvd., Room 4229, MSC 9550, Bethesda, MD 20892-
9550, 301-402-2105, rogersn2@nida.nih.gov.
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; Profile Screening and Predictive Toxicology (8909).
Date: February 12, 2013.
Time: 10:00 a.m. to 2:00 p.m.
Agenda: To review and evaluate contract proposals.
Place: National Institutes of Health, Neuroscience Center, 6001
Executive Boulevard, Rockville, MD 20852, (Telephone Conference
Call).
Contact Person: Lyle Furr, Contract Review Specialist, Office of
Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS,
Room 4227, MSC 9550, 6001 Executive Boulevard, Bethesda, MD 20892-
9550, (301) 435-1439, lf33c.nih.gov.
(Catalogue of Federal Domestic Assistance Program Nos.: 93.279, Drug
Abuse and Addiction Research Programs, National Institutes of
Health, HHS)
Dated: December 13, 2012.
Michelle Trout,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2012-30453 Filed 12-18-12; 8:45 am]
BILLING CODE 4140-01-P
